Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine vs sufentanil for PONV after hysteroscopic painless gynecologic procedures
ChiCTR2500096799Phase 4Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of oliceridine in postoperative nausea and vomiting (PONV) and postoperative pain (2 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: Incidence and severity of postoperative nausea and vomiting (PONV) within 24 hours. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
oliceridine
03
Conditions
postoperative nausea and vomiting (PONV)postoperative pain
Beyond the preview
Go deeper on ChiCTR2500096799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096799.